FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.

Saved in:
Bibliographic Details
Title: FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Authors: Sharma P; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Kanapuru B; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., George B; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Lin X; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Xu Z; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Bryan WW; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Pazdur R; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Theoret MR; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 May 02; Vol. 28 (9), pp. 1759-1764.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-21-3803